Disposition of debrisoquine and nortriptyline in Korean subjects in relation to <i>CYP2D6</i> genotypes, and comparison with Caucasians

Abstract

Heterozygosity for CYP2D6*10 decreases the CYP2D6-dependent elimination of nortriptyline and debrisoquine to only a limited degree. Further studies in subjects homozygous for CYP2D6*10 are required to elucidate fully the pharmacokinetic consequences of this CYP2D6 genotype in Orientals.